Data Insights
By Company Name
No Filter Selected
By Disease Name
No Filter Selected
By Drug Name
No Filter Selected
By Themes
No Filter Selected
Showing 1 results out of 1
Data Insights
Runcaciguat by Bayer for Non-Proliferative Diabetic Retinopathy (NPDR): Likelihood of Approval
Runcaciguat is under clinical development by Bayer and currently in Phase II for Non-Proliferative Diabetic Retinopathy (NPDR). According to GlobalData,...